8-KLeadership ChangesExhibits & Filings

Guardant Health, Inc. 8-K Report, Executive Changes (Jul 18, 2024)

Filed July 18, 2024For Securities:GH

Summary

Guardant Health, Inc. (GH) has announced a key change to its Board of Directors, appointing Dr. Manuel Hidalgo Medina as a Class II director. This appointment, effective July 17, 2024, expands the Board to nine members and brings significant expertise in anticancer drug development, particularly in gastrointestinal and pancreatic cancers, to the company's leadership. Dr. Hidalgo's extensive background includes leadership roles at prestigious institutions like Weill Cornell Medicine and Harvard Medical School, as well as experience with major pharmaceutical companies like Bristol-Myers Squibb. This strategic addition to the Board is expected to bolster Guardant Health's capabilities, especially in light of its focus on developing advanced cancer diagnostics and therapies. Dr. Hidalgo's compensation will include standard director awards of stock options and restricted stock units, valued at $362,500 collectively, vesting over a period of up to four years. The company also noted that there are no reportable arrangements or transactions involving Dr. Hidalgo that would require disclosure under Regulation S-K.

Key Highlights

  • 1Guardant Health appointed Dr. Manuel Hidalgo Medina to its Board of Directors as a Class II director, effective July 17, 2024.
  • 2The Board size has been increased to nine directors with this appointment.
  • 3Dr. Hidalgo brings over 20 years of experience in translational and clinical research in anticancer drug development, with a specialization in gastrointestinal cancers.
  • 4He currently serves as Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine and is the Walter B. Wriston Professor of Pancreatic Cancer Research.
  • 5Dr. Hidalgo also holds a board position at Bristol-Myers Squibb Company.
  • 6His compensation includes standard non-employee director awards of stock options and restricted stock units, each valued at $362,500.
  • 7The appointment is intended to enhance the Board's expertise in oncology and drug development.

Frequently Asked Questions

Guardant Health appointed Dr. Manuel Hidalgo Medina to its Board of Directors to leverage his extensive expertise in anticancer drug development, particularly in gastrointestinal and pancreatic cancers, to strengthen the Board's strategic guidance and oversight.

Dr. Hidalgo has over 20 years of experience in clinical research and drug development, holding senior positions at leading medical institutions like Weill Cornell Medicine and Harvard Medical School. His specialization in gastrointestinal cancers and experience in early clinical development of new anticancer agents are directly relevant to Guardant Health's mission in oncology diagnostics and therapeutics.

Dr. Hidalgo will receive the standard compensation for non-employee directors, which includes a stock option award and a restricted stock unit award, each valued at $362,500. These awards will vest over a period of up to four years, subject to continued service.

The filing states that there are no arrangements or understandings pursuant to which Dr. Hidalgo was selected other than his professional qualifications, and no reportable transactions under Regulation S-K. However, investors should note his ongoing board position at Bristol-Myers Squibb Company.